AUPH Aurinia Pharmaceuticals Inc

6.51
-0.19  -3%
Previous Close 6.70
Open 6.75
Price To book 3.14
Market Cap 546662062
Shares 83,972,667
Volume 1,479,070
Short Ratio 9.94
Av. Daily Volume 1,137,696

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

48-week data from open-label AURION study presented March 27, 2017 - primary endpoint met.
Voclosporin - AURION trial
Lupus
Phase 3 trial initiation announced May 15, 2017.
Voclosporin - AURORA
Lupus

Latest News

  1. Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options
  2. Aurinia Pharmaceuticals (AUPH) Looks Good: Stock Adds 7.8% in Session
  3. Today's Research Reports on Stocks to Watch: Inotek Pharmaceuticals and Aurinia Pharmaceuticals
  4. Can The Uptrend Continue for Aurinia Pharmaceuticals (AUPH)?
  5. Should You Buy Aurinia Pharmaceuticals Inc (AUPH)?
  6. Why High-Flying Aurinia Pharmaceuticals Stock Could Still Be Dirt Cheap
  7. Aurinia Receives National Corporate Visionary Award from the Lupus Foundation of America
  8. Aurinia Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AUPH) : October 2, 2017
  9. Aurinia Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AUPH-US : September 29, 2017
  10. Why Aurinia Pharmaceuticals Could Be a Gold Mine for Growth Investors
  11. Aurinia to Host R&D Day and Webcast on October 20th in New York, NY
  12. Should You Be Holding Aurinia Pharmaceuticals Inc (AUPH) Right Now?
  13. Aurinia to Webcast at Upcoming Investor Conferences
  14. 3 Charts That Show Why Aurinia Pharmaceuticals Stock Could Go Higher
  15. Aurinia Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : AUPH-US : September 1, 2017
  16. Market Bulls Continue on Quest for Strength
  17. Aurinia Pharmaceuticals, Inc. :AUPH-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
  18. 3 Reasons to Buy Aurinia Pharmaceuticals Stock Right Now
  19. Aurinia reports 2Q loss